Insmed Inc SEC Filings

Insmed Inc. director reports stock sales. A board member of Insmed Inc. (INSM) sold several blocks of common stock on November 17, 2025, at weighted average prices between $193.51 and $197.40 per share. After these open-market sales, the director’s directly held common stock decreased from 126,465 shares to 54,677 shares. The filing notes that detailed trade breakdowns within each price range are available to regulators, the company, or shareholders upon request.

Insmed Inc. (INSM) reported an insider stock sale by a company director. On 11/14/2025, the director sold 10,000 shares of common stock at a price of $195.87 per share, according to a Form 4 filing. After this transaction, the director continues to hold 63,729 shares directly. This filing simply records a change in the director’s personal holdings and does not, by itself, change the company’s operations or financial results.

Insmed Incorporated announced that the European Commission has approved its drug BRINSUPRI (brensocatib 25 mg tablets) to treat non-cystic fibrosis bronchiectasis in certain younger and adult patients. The approval covers patients 12 years of age and older who have experienced two or more exacerbations in the prior 12 months, addressing a population with recurrent respiratory flare-ups. Insmed disclosed the news in connection with a press release, which is included as an exhibit to the report.

Insmed (INSM) reported an insider transaction by its Chief People Strategy Officer on 11/12/2025. The officer exercised 30,000 stock options at an exercise price of $26.46 and received common shares. On the same day, the officer sold shares in four tranches at weighted average prices of $192.45 (4,078 shares), $193.64 (6,575), $194.44 (19,183), and $195.88 (164), with ranges disclosed for each tranche. Following these transactions, the officer directly owned 36,461 common shares. Remaining derivative holdings were 15,760 options expiring on 05/12/2031, which are currently exercisable as described.

Insmed Inc. (INSM) reported insider transactions by its Chief Medical Officer on 11/11/2025. The officer exercised stock options for 12,949 shares at $17.07 and 18,277 shares at $18.95 (transaction code M), then sold shares in open-market trades (transaction code S) under a Rule 10b5-1 plan adopted on February 27, 2025.

Sales were executed at weighted average prices of $188.38 for 5,467 shares (range $187.93–$188.90), $189.36 for 12,224 shares (range $188.90–$189.88), $190.33 for 10,622 shares (range $189.92–$190.90), and $191.04 for 2,913 shares (range $190.94–$191.14). Following these transactions, the officer reported 83,111 shares beneficially owned directly. The disclosed options carry expirations on 05/11/2032 and 05/11/2033, with vesting at 25% on the first anniversary and 12.5% each six months through the fourth anniversary.

Insmed (INSM) filed a Form 4 disclosing a gift transfer by a director. On 11/06/2025, the reporting person executed a Code G transaction, gifting 60,000 shares of common stock at $0.

Following the transaction, the director held 66,933 shares directly and 60,000 shares indirectly, listed as held by spouse revocable trust. The filing indicates a change in the form of ownership, not an open-market trade.

Insmed (INSM) reported an insider transaction by its Chief Legal Officer. On 11/03/2025, the officer exercised 27,130 stock options at an exercise price of $23.75 and sold shares in multiple tranches under a Rule 10b5-1 trading plan adopted on February 27, 2025.

The sales were executed at weighted average prices ranging from $181.01 to $187.97, with the filing noting price ranges and an undertaking to provide per-price breakdowns upon request. Following the reported transactions, the officer beneficially owned 54,902 shares directly.

Insmed Incorporated reported Q3 2025 results with product revenues, net of $142,342, up from $93,425 a year ago. ARIKAYCE delivered $114,291 (US $73,984; International $40,307), and the newly approved BRINSUPRI contributed $28,051 in its US launch quarter. Operating expenses rose sharply, including a $104,653 increase in the fair value of contingent consideration, leading to an operating loss of $366,005 and a net loss of $370,021. Basic and diluted net loss per share was $1.75 on 211,759 thousand weighted average shares.

Liquidity and capital structure shifted meaningfully. Cash and cash equivalents were $334,764 and marketable securities were $1,345,222 as of September 30, 2025. Long-term debt declined to $539,719 from $1,103,382 as the 0.75% 2028 notes were largely converted and then redeemed, while an amended senior term loan now carries a fixed 9.6% rate and matures in 2029. Shares outstanding were 212,583,015 as of September 30, 2025.

Pipeline and commercialization updates included FDA approval of BRINSUPRI on August 12, 2025 and continued global sales of ARIKAYCE. For the nine months ended September 30, 2025, product revenues, net were $342,580 versus $259,265, while operating cash use was $687,418, reflecting heavier R&D and SG&A to support launches and development.

Insmed Incorporated announced it has furnished a press release detailing its financial results for the third quarter ended September 30, 2025. The company also provided a slide presentation to accompany its conference call.

Both materials are included as Exhibits 99.1 and 99.2. The information is furnished under Item 2.02 and Item 9.01 and is not deemed “filed” for purposes of Section 18 of the Exchange Act.